NervGen Pharma Corp.

Restoring Life’s Potential by Enabling the Nervous System to Repair Itself after Neurologic Trauma and Disease

[NervGen Pharma Corp. @NervgenP]

NervGen today announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study.

Read the full news release: https://t.co/Jz4ulL2ZJK

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen today reported financial results for the first quarter ended March 31, 2026, and provided business updates.

Read the full news release: https://t.co/TT6eE3KJTi

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer to lead financial strategy and operations.

https://t.co/TPpxLDI8CR

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen today announced that Adam Rogers, MD, President and Chief Executive Officer, and other members of the Company’s executive leadership team, are scheduled to participate in a fireside chat during the virtual H.C. Wainwright “HCW@Home” series and present at the 2026 Bloom Burton & Co. Healthcare Investor Conference.

https://t.co/sUUju2Cy1a

#SCI

[NervGen Pharma Corp. @NervgenP]

NervGen today announced the completion of a successful End-of-Phase 2 (EOP2) meeting and alignment on RESTORE, the Company’s Phase 3 registrational study designed to evaluate NVG-291 for the treatment of chronic tetraplegia.

RESTORE initiation remains on-track for mid-2026, with study initiation activities underway.

Read the full news release: https://t.co/mOK1KpK6qg

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen Pharma today reported its full year 2025 financial results and provided business updates.

Read the full news release: https://t.co/pLFsxmFyQF

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen’s CEO, Dr. Adam Rogers, joined @biotechnation to share the story behind NVG-291, from Dr. Jerry Silver’s pioneering research and Harold Punnett’s founding vision to what NervGen’s CONNECT SCI clinical data now shows is possible for individuals living with chronic spinal cord injury.

https://t.co/yinHJwAdCg

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen Pharma today announced that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026.

The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN,” and no action is required by shareholders. All shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq.

Read the full news release: https://t.co/wo3hUQOW7j

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen today appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President (SVP), Patient Advocacy and Clinical Affairs.

https://t.co/vzhJF9JTCd

#SCI

[NervGen Pharma Corp. @NervgenP]

NervGen today announced that Adam Rogers, MD, President and Chief Executive Officer, and other members of the Company’s executive leadership team, are scheduled to participate in multiple upcoming investor conferences.

https://t.co/J8ikXWjTBX

#SCI

[NervGen Pharma Corp. @NervgenP]

NervGen today announced it will present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium, which is being held February 15-17, 2026, in Washington, DC.

https://t.co/Vz1uRIF3SL

#SCI #SpinalCordInjury #CNS #NeuroRepair #Biotech

[NervGen Pharma Corp. @NervgenP]

NervGen today announced it has appointed Adam Rogers, MD, as President and CEO. Dr. Rogers will continue leading the Company’s growth and execution of its mission to transform the lives of individuals living with spinal cord injury.

https://t.co/g9htTnysIC

#SCI

[NervGen Pharma Corp. @NervgenP]

🎉A proud moment for our team!

NervGen celebrated its @Nasdaq listing by ringing the closing bell yesterday in Times Square. A significant milestone and the beginning of an exciting year ahead.

View the full ceremony: https://t.co/qlHNHcOeCK

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen Pharma today announced that it will ring the closing bell at the Nasdaq Stock Market on Thursday, January 22, 2026, in New York City.

https://t.co/sO5rBT6Fb1

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen will be on the ground next week at #JPM2026 Jan 12-15 in San Francisco.

We look forward to connecting with global industry leaders as we continue advancing NVG-291 to transform the lives of individuals living with spinal cord injury.

#JPM26 #SCI

[NervGen Pharma Corp. @NervgenP]

NervGen Pharma today announced that the company's common shares have been approved for listing on Nasdaq and will begin trading today under the symbol “NGEN.”

https://t.co/acATzzpRmG

#SCI #SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

Thank you, @Forbes and @TheAlexKnapp, for featuring NVG-291 in this week’s edition of The Prototype!

[Forbes @Forbes]

This Company’s Drug May Help Regenerate Injured Spinal Cords https://t.co/NG34I2jchr

[NervGen Pharma Corp. @NervgenP]

NervGen CEO Adam Rogers spoke with @BioSpace about the unprecedented CONNECT SCI data showing NVG-291 improved function, independence & quality of life in chronic #SCI with reported durability up to 1 year after the 16-week study period.

https://t.co/9f40RWqRI5

#SpinalCordInjury

[NervGen Pharma Corp. @NervgenP]

NervGen reports its third quarter 2025 financial results and provides business updates.

Read the full release here: https://t.co/Bq9DmYWcCG

#SCI #SpinalCordInjury #News

[NervGen Pharma Corp. @NervgenP]

NervGen today announced expanded CONNECT SCI Study data demonstrating unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic SCI.

https://t.co/EACyqx3LkB

#SCI #SpinalCordInjury #News